CD4 and prostate carcinoma: In another trial evaluating ipilimumab in a variety of malignancies (colon, non-Hodgkin’s lymphoma, or prostate cancer), this treatment was found to induce a long-term decrease in CD4+ Tregs (CD4+CD25+CD62L+) (O’Mahony et al., 2007).